Triple-negative breast carcinoma
Information
- Disease name
- Triple-negative breast carcinoma
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03715959 | Active, not recruiting | N/A | Nipple Aspirate Fluid in Detecting Breast Cancer | July 25, 2019 | December 31, 2024 |
| NCT00861705 | Active, not recruiting | Phase 2 | Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery | May 15, 2009 | February 22, 2025 |
| NCT01116648 | Active, not recruiting | Phase 1/Phase 2 | Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer | April 14, 2010 | February 13, 2025 |
| NCT01349959 | Active, not recruiting | Phase 2 | Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer | April 21, 2011 | March 7, 2025 |
| NCT01750073 | Active, not recruiting | Phase 2 | Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer | December 7, 2012 | June 2026 |
| NCT02208375 | Active, not recruiting | Phase 1/Phase 2 | mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian | November 11, 2014 | December 30, 2025 |
| NCT02411656 | Active, not recruiting | Phase 2 | Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy | June 11, 2015 | December 31, 2028 |
| NCT02419495 | Active, not recruiting | Phase 1 | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies | June 26, 2015 | December 31, 2024 |
| NCT02432963 | Active, not recruiting | Phase 1 | Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy | June 14, 2016 | December 31, 2024 |
| NCT02445391 | Active, not recruiting | Phase 3 | Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy | October 20, 2015 | March 29, 2031 |
| NCT02488967 | Active, not recruiting | Phase 3 | Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer | July 26, 2015 | October 31, 2026 |
| NCT02498613 | Active, not recruiting | Phase 2 | A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors | August 31, 2016 | April 10, 2025 |
| NCT02530489 | Active, not recruiting | Phase 2 | Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer | February 4, 2016 | December 31, 2025 |
| NCT02593175 | Active, not recruiting | Phase 2 | Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC | August 26, 2016 | August 31, 2025 |
| NCT02744053 | Active, not recruiting | Early Phase 1 | DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer | November 7, 2016 | April 30, 2026 |
| NCT02876107 | Active, not recruiting | Phase 2 | Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer | October 6, 2016 | October 31, 2025 |
| NCT02883062 | Active, not recruiting | Phase 2 | Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer | August 2, 2017 | January 23, 2025 |
| NCT02954874 | Active, not recruiting | Phase 3 | Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer | January 18, 2017 | May 31, 2026 |
| NCT02957968 | Active, not recruiting | Phase 2 | Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca | January 24, 2017 | February 28, 2025 |
| NCT03012100 | Active, not recruiting | Phase 2 | Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer | March 31, 2017 | July 31, 2026 |
| NCT03218826 | Active, not recruiting | Phase 1 | PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery | September 24, 2018 | September 22, 2024 |
| NCT00576654 | Active, not recruiting | Phase 1 | Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery | December 5, 2007 | June 30, 2023 |
| NCT04052555 | Active, not recruiting | Phase 1 | Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer | September 24, 2020 | November 20, 2024 |
| NCT04216472 | Active, not recruiting | Phase 2 | Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations | February 5, 2020 | December 31, 2025 |
| NCT04491942 | Active, not recruiting | Phase 1 | Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer | August 25, 2021 | June 30, 2025 |
| NCT04835597 | Active, not recruiting | Precision Performance Status Assessment in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy | August 15, 2022 | December 31, 2026 | |
| NCT05086731 | Active, not recruiting | N/A | Mobile Health to Improve Oral Chemotherapy Adherence Among Women With Breast Cancer | October 22, 2021 | December 31, 2024 |
| NCT00892736 | Completed | Phase 1 | Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy | April 20, 2009 | May 19, 2017 |
| NCT01624441 | Completed | Phase 1 | Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer | August 21, 2012 | September 10, 2013 |
| NCT03207529 | Completed | Phase 1 | Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer | June 7, 2019 | December 31, 2023 |
| NCT01145430 | Completed | Phase 1 | Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer | June 1, 2010 | |
| NCT01575522 | Completed | Phase 2 | Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer | March 2012 | July 2013 |
| NCT01251874 | Completed | Phase 1 | Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer | November 16, 2010 | April 12, 2017 |
| NCT01276496 | Completed | Phase 1 | Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery | December 2010 | |
| NCT01281150 | Completed | Phase 1 | Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors | January 2011 | |
| NCT02648477 | Completed | Phase 2 | Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer | March 28, 2016 | December 30, 2023 |
| NCT02672475 | Completed | Phase 1 | Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer | March 2016 | August 2023 |
| NCT02689427 | Completed | Phase 2 | Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer | September 22, 2016 | November 15, 2023 |
| NCT03291938 | Completed | Phase 1 | IACS-010759 in Advanced Cancers | November 13, 2017 | November 23, 2020 |
| NCT02120469 | Completed | Phase 1 | Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer | October 1, 2014 | March 3, 2020 |
| NCT02456857 | Completed | Phase 2 | Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative | January 12, 2016 | May 24, 2023 |
| NCT03872388 | Completed | Phase 2 | Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy | January 14, 2019 | October 19, 2023 |
| NCT04081389 | Completed | Phase 1 | Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer | December 6, 2019 | February 27, 2023 |
| NCT02599194 | Completed | Phase 2 | 18F-FSPG PET/CT for Cancer Patients on Therapy | July 2015 | December 14, 2016 |
| NCT03544125 | Completed | Phase 1 | Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer | May 3, 2018 | November 18, 2020 |
| NCT02996825 | Completed | Phase 1 | Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer | March 22, 2017 | February 9, 2024 |
| NCT05071677 | Completed | Treatment Decision Making in African American Women Diagnosed With Triple Negative Breast Cancer | May 3, 2021 | August 7, 2023 | |
| NCT03012230 | Completed | Phase 1 | Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer | December 6, 2017 | March 8, 2023 |
| NCT01964924 | Completed | Phase 2 | Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer | October 2, 2013 | April 23, 2018 |
| NCT03106077 | Completed | Phase 2 | Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer | June 5, 2017 | October 1, 2019 |
| NCT01846091 | Completed | Phase 1 | Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer | April 9, 2013 | November 26, 2019 |
| NCT06422455 | Not yet recruiting | N/A | Access to Genetic Testing in Underserved Patients With Cancer | July 1, 2024 | July 1, 2027 |
| NCT02276443 | Recruiting | N/A | Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative | November 9, 2015 | November 30, 2026 |
| NCT03971409 | Recruiting | Phase 2 | Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer | July 8, 2019 | June 30, 2025 |
| NCT03979508 | Recruiting | Phase 2 | Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer | January 10, 2020 | July 31, 2024 |
| NCT05269381 | Recruiting | Phase 1/Phase 2 | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors | March 31, 2022 | February 24, 2026 |
| NCT02945579 | Recruiting | N/A | Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy | January 20, 2017 | January 31, 2026 |
| NCT05455658 | Recruiting | Phase 2 | STEMVAC in Patients With Early Stage Triple Negative Breast Cancer | November 17, 2022 | December 31, 2025 |
| NCT05677802 | Recruiting | N/A | Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast Cancer | December 14, 2022 | December 31, 2024 |
| NCT02993068 | Recruiting | N/A | Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible) | April 18, 2017 | April 18, 2024 |
| NCT03213041 | Recruiting | Phase 2 | Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer | September 14, 2017 | July 2023 |
| NCT05111561 | Recruiting | Phase 1 | Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer | August 2, 2022 | March 14, 2025 |
| NCT01238133 | Terminated | Phase 1 | Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast Cancer | December 2010 | August 2015 |
| NCT01071564 | Terminated | Phase 1 | RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery | November 2009 | June 2014 |
| NCT03199040 | Terminated | Phase 1 | Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy | July 23, 2019 | May 1, 2023 |
| NCT01957514 | Terminated | Collecting, Analyzing, and Storing Samples From Patients With Metastatic, Triple Negative Breast Cancer Receiving Anti-cancer Therapy | October 28, 2013 | June 30, 2018 | |
| NCT04185311 | Terminated | Phase 1 | Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted | July 10, 2019 | May 17, 2023 |
| NCT04139993 | Terminated | Phase 1 | RBX7455 Before Surgery for the Treatment of Operable Breast Cancer | August 31, 2020 | January 11, 2023 |
| NCT02474173 | Terminated | Phase 1 | Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer | January 15, 2016 | October 26, 2022 |
| NCT02457910 | Terminated | Phase 1/Phase 2 | Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer | June 2015 | August 8, 2022 |
| NCT01319539 | Terminated | Phase 2 | MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer | April 2011 | July 2013 |
| NCT03154190 | Unknown status | N/A | Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer | August 8, 2017 | August 30, 2022 |
| NCT03044730 | Unknown status | Phase 2 | Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery | May 25, 2017 | May 2021 |
| NCT03326258 | Withdrawn | Phase 1/Phase 2 | Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery | April 20, 2018 | April 20, 2018 |
| NCT02627430 | Withdrawn | Phase 1 | Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer | March 2016 | |
| NCT05177796 | Withdrawn | Phase 2 | Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer | March 11, 2022 | July 26, 2023 |
| NCT02567396 | Withdrawn | Phase 1 | Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction | June 2016 |